Medical articles prepared for cell adhesion

Details Medical articles prepared for cell adhesion Medical articles prepared for cell adhesion

1999-12-13

2004-04-27

Willse, David H. (Department: 3738)

Prosthesis (i.e., artificial body members), parts thereof, or ai

Heart valve

Specific material for heart valve

C623S023560, C623S023570, C623S023760

Reexamination Certificate

active

06726718

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to medical articles having components that have been modified with a compound that stimulates cell adhesion, such as a structural protein or a polypeptide growth factor. The invention further relates to methods for producing these medical articles.
BACKGROUND OF THE INVENTION
Prostheses, i.e., prosthetic devices, are used to repair or replace damaged or diseased organs, tissues and other structures in humans and animals. Prostheses must be generally biocompatible since they are typically implanted for extended periods of time. Prostheses can be constructed from natural materials such as tissue, synthetic materials or a combination thereof. For example, prostheses, such as mechanical heart valve prostheses, are manufactured from biocompatible metals and other materials, such as pyrolytic carbon coated graphite and polyester. Mechanical heart valves generally include an occluder that pivots within an orifice ring, through which blood flows. Pivoting of the occluder opens and closes the valve.
Although mechanical heart valves have the advantage of proven durability through decades of use, they are associated with a potential for blood clotting on or around the prosthetic valve. Blood clotting can lead to acute or subacute closure of the valve or associated blood vessel. For this reason, patients with implanted mechanical heart valves remain on anticoagulants after implantation of the valve. Anticoagulants impart a potential risk of significant bleeding complications and cannot be taken safely by certain individuals. Occluders and orifice rings of mechanical heart valves can be formed from materials, such as pyrolytic carbon, that reduce the risk of blood clotting by the nature of their relative thromboresistance.
In addition to heart valve prostheses formed with rigid occluders, heart valve prostheses can be constructed from tissue or flexible polymer materials. Thrombosis and calcification are concerns associated with polymer heart valves. Tissue-derived prosthetic heart valves generally have blood flow characteristics and surface properties that provide a high degree of thromboresistance without the need for anticoagulant therapy. Therefore, thrombosis or thromboembolism and bleeding complications are less likely to occur than with mechanical heart valves. Unfortunately, prosthetic tissue heart valves are limited by a tendency to fail beginning about seven to ten years following implantation. Valve degeneration is particularly rapid in young patients and during pregnancy. Calcification, i.e., the deposition of calcium salts, especially calcium phosphate (hydroxyapatite), appears to be a major cause of degeneration. Flexible polymer heart valves also tend to fail due to calcification and subsequent degeneration.
Native heart valve tissue with viable cells has natural protection against calcification. Endothelial cells that coat the blood contacting surfaces of a native valve provide a barrier against calcification. These cells also protect against infection and provide active thromboresistance.
SUMMARY OF THE INVENTION
In a first aspect, the invention pertains to a medical article suitable for contacting a patient's bodily fluids. The medical article includes a biocompatible material and at least one cell adhesion stimulating protein associated with the biocompatible material. The biocompatible material includes a ceramic material over at least part of its surface.
In another aspect, the invention pertains to a method for producing a medical article suitable for contact with a patient's bodily fluids. The method includes the adhering of a cell adhesion stimulating protein to a ceramic material.
In a further aspect, the invention pertains to a method for producing a prosthesis. The method includes the harvesting of viable cells from a patient and the adhering of a cell adhesion stimulating protein to a ceramic material. The method further includes the associating of the viable cells with the ceramic material by contacting the ceramic material having adhered protein with a cell culture comprising the viable cells.


REFERENCES:
patent: 3685059 (1972-08-01), Bokros et al.
patent: 4620327 (1986-11-01), Caplan et al.
patent: 4648881 (1987-03-01), Carpentier et al.
patent: 4798611 (1989-01-01), Freeman, Jr.
patent: 5002582 (1991-03-01), Guire et al.
patent: 5080668 (1992-01-01), Bolz et al.
patent: 5147400 (1992-09-01), Kaplan et al.
patent: 5147514 (1992-09-01), Mechanic
patent: 5192312 (1993-03-01), Orton
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5607469 (1997-03-01), Frey
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5613982 (1997-03-01), Goldstein
patent: 5648301 (1997-07-01), Ducheyne et al.
patent: 5728152 (1998-03-01), Mirsch, II et al.
patent: 5728420 (1998-03-01), Keogh
patent: 5759205 (1998-06-01), Valentini
patent: 5811151 (1998-09-01), Hendricks et al.
patent: 5817327 (1998-10-01), Ducheyne et al.
patent: 5899939 (1999-05-01), Boyce et al.
patent: 6013106 (2000-01-01), Tweden et al.
patent: 6033719 (2000-03-01), Keogh
patent: 6413538 (2002-07-01), Garcia et al.
patent: 0 476 983 (1992-03-01), None
patent: 0 506 477 (1992-09-01), None
patent: 0 550 296 (1993-07-01), None
patent: 0 616 814 (1994-09-01), None
patent: 0 742 020 (1996-11-01), None
patent: WO-99/37337 (1999-07-01), None
patent: WO 86/00526 (1986-01-01), None
patent: WO 95/24473 (1995-09-01), None
patent: 95/31944 (1995-11-01), None
patent: 98/52619 (1998-11-01), None
patent: 99/37337 (1999-07-01), None
“Endothelialization of Mechanical Heart Valves In Vitro with Cultured Adult Human Cells”, Bengtsson et al., The Journal of Heart Valve Disease, vol. 2, No. 3, pp. 352-356, May 1993.*
“Accelerated Endothelialization by Local Delivery of Recombinant Human Vascular Endothelial Growth Factor Reduces In-Stent Intimal Formation” by, Bell et al., Biochemical and Bio Physical Research Communication 235, 311-316 (1997).
“Conditional Switching of Vascular Endothelial Growth Factor (VEGF) Expression in Tumors: Induction of Endothelial Cell Shedding and Regression of Hemangioblastoma-like Vessels by VEGF Withdrawal” by, Benjamin et al., Proc. Natl. Acad. Sci. USA, vol. 94. pp. 8761-8766, Aug. 1997, Medical Sciences.
“Endothelialization of Mechanical Hear Valves In Vitro with Cultured Adult Human, Cells” by, Bengtsson et al., The Journal of Heart Valve Disease, vol. 2, No. 3, pp. 352-356, May 1993.
“Passivation of Metallic Stents After Arterial Gene Transfer of phVEGF165Inhibits Thrombus Formation and Intimal Thickening” by, VanBelle et al., JACC vol. 29, No. 6, May 1997:1371-1379.
“Stent Endothelialization: Time Course, Impact of Local Catheter Deliver, Feasibility of Recombinant Protein Administration, and Response to Cytokine Expedition” by, Van Belle et al., Circulation, vol. 95. No. 2 Jan. 21, 1997, pp. 438-448.
“Stimulation of Endothelial Cell Migration by Vascular Permeability Factor/Vascular Endothelial Growth Factor through Cooperative Mechanisms Involving the &agr;v&bgr;3Integrin, Osteopontin, and Thrombin” by, Senger et al., American Journal of Pathology, vol. 149, No. 1, Jul. 1996, pp. 293-305.
“Synergistic Effect of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on Angiogenesis in Vivo” by, Asahara et al., Supplemental II Circulation vol. 92, No. 9, Nov. 1, 1995, pp. 365-371.
“Vascular Endothelial Growth Factor and Heparin in a Biologic Glue Promotes Human Aortic Endothelial Cell Proliferation with Aortic Smooth Muscle Cell Inhibition” by, Weatherford et al., Surgery, vol. 120, No. 2, pp. 433-439 (Aug. 1996).
“Vascular Endothelial Growth Factor Inhibits Endothelial Cell Apoptosis Induced by Tumor Necrosis Factor &agr;: Balance Between Growth and Death Signals” by, Spyridopoulos et al., J. Mol. Cell. Cardiol., vol. 29, 1321-1330 (1997).
“Vascular Permeability Factor/Vascular Endothelial Growth Factor Inhibits Anchorage-Disruption-Induced Apoptosis in Microvessel Endothelial Cells by Inducing Scaffold Formation”, by Watanabe et al., Experimental Cell Research 233, pp. 340-349 (1997).
“Vascular Permeability Factor/Vascul

Affiliated with

Also associated with

Rating

Medical articles prepared for cell adhesion does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medical articles prepared for cell adhesion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical articles prepared for cell adhesion will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3188730